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Abstract: Background: Fatigue is one of the major health conditions induced by excessive stress or
abnormal immune function or defective antioxidant systems. Placental extract has been reported
to have various effects such as immune modulation and cellular regeneration. Fermented porcine
placenta (FPP) is a safe nontoxic material, which is highly valuable as a functional food. The aim of
this study was to investigate the anti-fatigue effects of FPP supplementation compared with a placebo
product. Methods: In this double-blind, parallel, randomized, and placebo-controlled trial 84 healthy
males and females, aged between 30 and 60 years were randomized to 320 mg of FPP once daily or
placebo. The main outcome measures included efficacy of fatigue-inducing treadmill exercise on
physical fatigue and fatigue-related parameters based on the questionnaire administered. Results:
The IL-1β mRNA expression and fatigue severity scale were changed significantly after 8 weeks
of treatment with fermented porcine placenta compared with placebo (p < 0.05). Cortisol levels
were significantly improved in participants younger than 45 years following treatment with FPP
compared with placebo. Furthermore, the lactate and myoglobin levels were improved significantly in
participants with BMI ≥ 23 kg/m2 (p = 0.045 and p = 0.011, respectively) following treatment with FPP
versus placebo. Conclusions: Our study showed that FPP supplementation significantly ameliorated
fatigue-related parameters and subjective symptoms in healthy adults. Therefore, our results indicate
that FPP supplementation induced anti-fatigue effect by regulating the inflammatory response.
Keywords: daily fatigue; fermented porcine placenta; physical fatigue; inflammatory cytokine;
treadmill test

1. Introduction
Fatigue is a subjective individual symptom characterized by an overwhelming and sustained
tiredness, which decreases the physical and mental effectiveness that is not resolved by rest [1].
In modern society, it has become an occupational risk factor as well as a personal challenge. Although
fatigue is a frequent symptom in patients diagnosed with multiple sclerosis [2], cancer [3], and other
diseases [4,5], it is also common in the healthy individuals, including 14.3% of male and 20.4% of
female subjects [6]. Moreover, it has negative effects on physical and mental activities of daily life,
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which is closely related to the quality of life [7]. Numerous factors, including interleukin 1 (IL-1),
C-reactive protein, and interferon γ levels are associated with fatigue [8].
Among the many other clinically available dietary supplements for reducing fatigue, such as
caffeine [9,10], theobromine [11], flavanols [12,13], and taurine [14], the placenta has been widely
used and commonly available in the health food market with its extensive use against immune
disorders and for wound healing and cellular regeneration [15]. The placenta is a vital barrier in the
fetus during the gestation period, contributing growth and development of the fetus via exchange
gases, nutrients, and waste with their mother via blood [15,16]. Furthermore, it is a well-known
source of bioactive compounds, including growth factors, functional peptides, and hormones for fetus
growth and development [17]. Porcine placental extract (PPE) is one of the clinically available dietary
supplements [15,18], in common with other placental extracts, known for its effectiveness in preventing
bone low, enhancing liver function, and hydrating skin [15,19,20].
Fermentation is one of the oldest methods of food preservation along with drying and salting,
and is associated with decent flavor, aroma and texture in food industry [21,22]. Fermented porcine
placenta (FPP) is receiving more attention due to its health benefits such as altered protein content via
fermentation [23]. In addition, FPP is a safe nontoxic material and is highly sought as a functional
food [15]. In animal models of exercise-induced physical fatigue, the intake of FPP has been found to
improve fatigue and reduced biochemical parameters, such as lactate, lactate dehydrogenase (LDH),
glucose, creatine kinase (CK), blood urea nitrogen (BUN), cortisol, and inflammatory cytokines after
treadmill stress test [23]. Moreover, a study by Nam et al. [24] reported that the major bioactive
compounds in FPP, such as Glycyl-L-Leucine (Gly-Leu, GL) and L-Leucylglycine (Leu-Gly, LG) elevated
nitric oxide (NO) production and inducible nitric oxide synthase expression and increased the activity
of superoxide dismutase (SOD) in RAW264.7 macrophages. In case of mouse model, the dipeptides
decreased the serum concentrations of IL-1β, IL-6, and NO and improved the levels of SOD and
glycogen, while decreasing the levels of lactate dehydrogenase, aspartate transaminase, and alanine
transaminase [24]. Although animal studies have demonstrated the potential of FPP as anti-fatigue
supplements, no reports have investigated its anti-fatigue effect on humans after a single bout of
exhaustive exercise. Consequently, the objective of this study was to elucidate the effect of FPP and its
major dipeptides, GL and LG, on fatigue and determine its safety in healthy adults. We hypothesized
that an eight-week supplementation with FPP has a positive anti-fatigue effect.
2. Materials and Methods
2.1. Study Design
The study was conducted as a randomized, double-blind, placebo-controlled, 8-week clinical trial
from December of 2016 to November of 2017. A total of four study observations were made: during
the screening, before ingestion (baseline), four weeks after ingestion, and eight weeks after ingestion.
The measurement site was the Seoul National University (Seoul, Korea). In this study, ethics approval
was obtained from the Institutional Review Board of Seoul National University, and each participant
provided signed informed consent during enrollment (SNUIRB No. 1609/002-019) (KCT0005372).
2.2. Study Sample
This study is to investigate the anti-fatigue effect of FPP on the population group with high
fatigue. It has been shown that Korean population over 30 years old have higher fatigue compared to
other population groups [25]. We have recruited healthy males and females aged 30 to 60 years who
complained of fatigue for the study (Fatigue Severity Scale (FSS) ≥ 27 points).
Eighty-four out of 110 applicants were screened according to inclusion and exclusion criteria.
Exclusion criteria were inability to perform treadmill test; increased cardiovascular endurance (up to
grade 1 and 2 to 50% of VO2 max depending on age); cardiovascular disease, endocrine/metabolic
disease, chronic lung disease, acute or chronic kidney disease; surgery within 6 months; treatment
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Table 1. Baseline characteristics of subjects 1.
appropriate quantity and quality before the start of the study.
Placebo
FPP
n = 31 (42)3
n = 36 (42)3
1.
Table 1. Baseline
characteristics
subjects
Age, mean ± SE
44.4 ± 1.3 (43.5
± 1.3)
41.3of
± 1.5
(41.7 ± 1.2)
Female, n (%)
32 (88.9%) (35 (83.3%))
26 (83.9%) (35 (83.3%))
BMI (kg/m2)
22.8 ± 0.4
(23.1 ± 0.4)
22.3 ± 0.5 (22.5
± 0.4)
FPP
Placebo
Alcohol drinker (Y/N)
/ 21)3
13 / 18 (23 / 19)
n16=/ 20
36(21
(42)
n = 31 (42) 3
Alcohol amount (g/week)
12.8 ± 3.8 (22.6 ± 7.7)
14.3 ± 6.0 (24.2 ± 7.8)

Age, mean ± SE
Female, n (%)
BMI (kg/m2 )
Alcohol drinker (Y/N)
Alcohol amount (g/week)
Recommended Food Score
Fatigue Severity Scale
VO2 max (mL/kg/min)
1

44.4 ± 1.3 (43.5 ± 1.3)
32 (88.9%) (35 (83.3%))
22.8 ± 0.4 (23.1 ± 0.4)
16/20 (21/21)
12.8 ± 3.8 (22.6 ± 7.7)
22.8 ± 1.2 (23.9 ± 1.2)
43.5 ± 1.5 (42.8 ± 1.5)
31.6 ± 0.8 (32.2 ± 0.9)

P-value 2
0.113 (0.311)
0.723 (0.100)
0.400 (0.225)
p-Value 2
1.000 (0.662)
0.955 (0.707)

41.3 ± 1.5 (41.7 ± 1.2)
26 (83.9%) (35 (83.3%))
22.3 ± 0.5 (22.5 ± 0.4)
13/18 (23/19)
14.3 ± 6.0 (24.2 ± 7.8)
25.4 ± 1.5 (25.5 ± 1.1)
40.3 ± 1.5 (42.5 ± 1.3)
33.3 ± 0.9 (33.5 ± 0.8)

0.113 (0.311)
0.723 (0.100)
0.400 (0.225)
1.000 (0.662)
0.955 (0.707)
0.141 (0.309)
0.134 (0.877)
0.165 (0.213)

Mean ± SE (all such values). FPP, fermented porcine placenta; BMI, body mass index. 2 Student’s t-test for
continuous variables and Chi-square or Fisher’s exact test for categorical variables were used to compare the
difference between the groups. 3 The numbers in parentheses indicate the mean and standard error of each group
after random allocation.
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2.3. Test Product
The test food and placebo were prepared as tablets. Supplements could not be distinguished
by appearance, shape or color. Test food tablets contained 80 mg of FPP (Horus Co., Ltd., Tokyo,
Japan), while placebo tablets included microcrystalline cellulose instead. The intake of each test
sample once daily was 4 tablets; therefore, the intake of FPP was 320 mg (containing 200 µg of
dipeptides (Gly-Leu+Leu-Gly)/day). Furthermore, the supplements (placebo or FPP) were distributed
to participants after each fatigue-inducing protocol (week 0, week 4), and the compliance was checked
at week 4 and the end of experiment.
2.4. Measurements
2.4.1. Body Composition
Bioelectrical impendence in individuals was measured using an InBody 720 apparatus analyzer
(Biospace Co. Ltd., Seoul, Korea). The participants were asked to fast overnight and engage in normal
physical activity. All anthropometric measurements were evaluated by the same person throughout
the study to minimize interpersonal variations. The participant’s height was determined using an
extensometer, and age, gender, and height were entered into the machine. Once impedance was
measured, the results of bodyweight, (BMI), fat mass (FM), fat-free mass (FFM) and percent body fat
(% BF) at five different body locations including each arm, each leg, and the trunk as well as a general
overall set were acquired [26].
2.4.2. Pre-Testing Protocol
Participant’s maximal exercise capacity was determined by measuring maximal oxygen
consumption (VO2 max) via exercise on a treadmill using T 150 Cosmed and Quark series Breath
Pulmonary Gas Exchange for functional diagnostics, until maximal exertion (voluntary cessation).
The modified Bruce protocol was used on a treadmill as described in a previous study [25]. To ensure
that each subject achieved maximal exertion, at least three of the following four criteria were met
by each subject: (1) a plateau in VO2 with increasing exercise intensity (<100 mL), (2) a respiratory
exchange ratio of at least 1.15, (3) a maximal respiratory rate of at least 35 breaths/min, and (4) a rating
of perceived exertion of at least 12 units on the Borg (6–20) scale [25].
2.4.3. Fatigue-Inducing Protocol
Fourteen days after their pre-testing, participants returned between 7:00 am and 10:00 am to
exercise on the treadmill for 30 min at 70% of their VO2 max, normally rated as “somewhat hard (12–14
on the scale)” on 6–20 scaled Borg’s perceived exertion scale [27]. Physical fatigue tests were conducted
in 0 and 8 weeks.
2.4.4. Primary and Secondary Outcomes
Blood samples were taken at rest, and immediately following exercise cessation, and after 15
and 30 min of recovery to assess physical fatigue. We investigated the serum biochemical profiles,
including lactate, (LDH), (CK), myoglobin, TNF-α, SOD, glucose, cortisol, and the serum levels of
IL-1β mRNA expression of all the subjects. Participants refrained from consuming nicotine, caffeine,
or alcohol, and from vigorous exercise 24 h prior to the exercise test.
Subjective fatigue was evaluated using FSS and Checklist Individual Strength (CIS) based on a total
of four measurements: screening, before ingestion (baseline), four weeks after ingestion and eight weeks
after ingestion. A recent bibliographic study of fatigue measurement scales suggests that FSS is the
most commonly used fatigue specific questionnaire [28]. The FSS is a self-administered questionnaire
comprising 9 items (questions) investigating the severity of fatigue in different situations during the
past week. Grading of each item ranges from 1 to 7, where 1 indicates strong disagreement and

Nutrients 2020, 12, 3086

5 of 15

7 suggesting strong agreement, with the final score representing the mean value of the 9 items. The CIS
was developed as a self-reported multidimensional instrument to assess four qualitatively different and
relevant aspects of fatigue: fatigue severity (subjective experience of fatigue), concentration problems,
reduced motivation, and reduced activity level [29]. It consists of 20 items (questions), each graded
1 to 7, where 1 indicates strong disagreement and 7 strong agreement. The items were designed to
measure these dimensions of fatigue.
General biochemical examination of blood and hematologic tests were performed for safety
evaluation. Fasting (>12 h) blood and urine samples were collected at baseline and after 8 weeks of
intervention. Biochemical parameters were the following: white blood cell count (WBC), red blood cell
count (RBC), hemoglobin amount (Hb), hematocrit (Ht), mean red blood cell volume (MCV), mean red
blood cell hemoglobin (MCH), mean red blood cell hemoglobin concentration (MCHC), platelet
count (PLT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glucose, creatinine,
(BUN), sodium (Na), potassium (K), protein, glucose, ketone, bilirubin, urobilinogen, nitrite, leukocyte
esterase, blood color, and pH. The safety of the supplement and the assessment of adverse symptoms
were examined via blood and urine analyses, the responsible physician’s inquiries, and subjects’
daily diaries.
The subject’s physical activity levels and diet were measured as possible covariate. Physical
activity level was assessed in week 4 and week 8 using International Physical Activity Questionnaire
(IPAQ) [30]. Furthermore, dietary intake was assessed for 3 days before testing using a 24-h recall
method, and protein intake (g), carbohydrate intake (g), and total calories (kcal) were assessed.
2.5. Statistical Analyses
To calculate the sample size, we have used the data from two previous studies, one investigating the
effect of the experimental supplement on serum lactate level after treadmill exercise [31], two investigating
FSS score after ingesting experimental supplement and placebo [32]. In Leelarungrayub et al. study [31],
the alteration of lactate in the experimental group and placebo group was −1.11 mmol/L and 0.12 mmol/L,
respectively. We anticipated −1.23 ± 1.72 mmol/L change based on this data after 8 weeks of intervention.
To achieve a 90% power and an alpha level of 0.05 (two-tailed), we calculated that 31 subjects are
required for each group. Furthermore, based on Zifko et al. study [32], we anticipated −4.30 ± 5.85
changes after 8 weeks of intervention, we calculated that 30 subjects are required for each group. As a
result, considering 25% drop-out rate, a total of 84 subjects were recruited and a total of 67 subjects
were analyzed (FPP group = 36, Placebo group = 31).
Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Basic characteristics of the study sample were stratified according to treatment with FPP supplement
and Placebo and compared using the x2 test (categorical variables) and Student’s t test (continuous
variables). A linear mixed-effects model including all time points (rest to 30 min; group and time as
fixed factors and subject as a random factor) was used to determine the treatment effects. The efficacy
assessment was performed via a per-protocol set (PPS) analysis. Exclusion criteria for the PPS analysis
were unexpected events or actions affecting fatigue measurement or failure to participate on the
designated date and time due to personal circumstances, or test compliance below 80%. Safety
assessments were conducted via intent-to-treat (ITT) analysis. Data are shown as the least squares
means (LSmean) ± standard error (SE). Threshold for statistical significance was considered at a p-value
< 0.05.
3. Results
Table 2 presents the results of blood lactate levels before and 30 min after recovery following
treadmill exercise. The overall lactate level of area under the curve (AUC), the lactate level of the
AUC during the fatigue load due to treadmill exercise (pre-peak AUC), and the lactate level of the
AUC post-exercise until the recovery phase (post-peak AUC) were analyzed. FPP supplementation
demonstrated a decreased tendency in pre-peak AUC (p = 0.074).
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Table 2. Fermented porcine placenta effects for the lactate between groups 1 .
Variables
AUC (mg/dL × min)
Week 0
Week 8
Pre-peak AUC
(mg/dL × min)
Week 0
Week 8
Post-peak AUC
(mg/dL × min)
Week 0
Week 8

p-Value 2

FPP
Mean ± SE

Placebo
Mean ± SE

Group

Time

Group × Time

1103.1 ± 79.9
1064.6 ± 79.2

1105.6 ± 85.0
1177.8 ± 85.4

0.573

0.779

0.322

473.0 ± 64.7
370.0 ± 64.1

379.6 ± 68.7
462.9 ± 69.0

0.998

0.857

0.074

639.3 ± 51.1
691.1 ± 50.6

726.3 ± 54.2
707.8 ± 54.5

0.367

0.739

0.462

1

LSmean ± SE (all such values). FPP, fermented porcine placenta; AUC, area under the curve; pre-peak AUC,
AUC before peak concentration; post-peak AUC, AUC after peak concentration. 2 Linear mixed-effect model
adjusted for dietary intake and physical activity (MET) was used to analyze group, time and group × time for
8 weeks.

The IL-1β mRNA expression showed significant group × time interaction after 8 weeks of
treatment (p = 0.005). However, no significant changes (time × group interaction; p > 0.05) in IL-1β
mRNA expression were observed between the FPP group and placebo groups at week zero (Table 3).
Table 3. Fermented porcine placenta effects for the IL-1β mRNA expression between groups 1 .

Week 0
Resting state
End of exercise
Recovery 30 min
Week 8
Resting state
End of exercise
Recovery 30 min

p-Value 2

FPP
Mean ± SE

Placebo
Mean ± SE

Group

Time

Group × Time

1.60 ± 0.11
1.62 ± 0.11
1.74 ± 0.11

1.74 ± 0.12
1.80 ± 0.12
1.95 ± 0.12

0.256

0.001

0.755

1.77 ± 0.10
1.72 ± 0.10
1.79 ± 0.10

1.62 ± 0.11
1.64 ± 0.11
1.90 ± 0.11

0.780

0.004

0.005

1

LSmean ± SE (all such values). FPP, fermented porcine placenta; IL-1β, interleukin-1β. Relative value of IL-1β
mRNA expression compared to β-actin (×103 ). 2 Linear mixed-effect model adjusted for dietary intake and physical
activity (MET) was used to analyze group, time and group × time at week 0 and week 8.

Table 4 shows the LSmean ± SE values representing changes in FSS pre- and post-supplementation.
The internal consistency for FSS and CIS questionaries was tested, and Cronbach’s Alpha was 0.916
and 0.891, respectively. There was no difference in the total FFS score between the groups in baseline
(43.5 ± 1.5 vs. 40.3 ± 1.5, p = 0.134). However, after the 8 weeks of supplement intakes, significant
differences were found between the FPP and placebo groups in changes of total FSS scores (p = 0.046),
score for the question “my motivation is lower when I am fatigued” (p = 0.023), and “fatigue interferes
with my physical functioning” (p = 0.03). Furthermore, FPP ingestion reduced total FFS score by
9.15 ± 1.27 at 4th week and 9.79 ± 1.28 at the 8th week compared to baseline, whereas only 4.34 ± 1.38
at 4th week and 5.20 ± 1.38 at 8th week were reduced in placebo group. Similarly, the score for the
question “my motivation is lower when I am fatigued” showed larger changes overtime point in
the FPP group (baseline vs. 4th week, −0.98 ± 0.16; baseline vs. 8th week, −1.30 ± 0.20) compared
to the placebo group (baseline vs. 4th week, −0.19 ± 0.18; baseline vs. 8th week, −0.43 ± 0.21).
In addition, the score for the question “fatigue interferes with my physical functioning” also showed
larger changes overtime points in the FPP group (baseline vs. 4th week, −1.11 ± 0.16; baseline vs. 8th
week, −1.33 ± 0.20) compared to the placebo group (baseline vs. 4th week, −0.52 ± 0.18; baseline vs.
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8th week, −0.79 ± 0.22) (Table 4). Lastly, the CIS subscale used to measure the subjective experience of
fatigue showed a tendency to decrease after eight weeks of ingestion in the FPP intervention group
(p = 0.073). A significant improvement was observed in items including “physically, I feel exhausted”
(p = 0.021), and “I feel weak” (p = 0.019) (Table A1).
Table 4. Changes of Fatigue Severity Scale between groups 1 .
Variables

FPP
Mean ± SE

Placebo
Mean ± SE

p-Value 2
Group

Time

Group × Time

Total
Week 4
−9.15 ± 1.27 −4.34 ± 1.38
Week 8
−9.79 ± 1.28 −5.20 ± 1.38
0.026
<0.001
1. My motivation is lower when I am fatigued.
Week 4
−0.98 ± 0.16 −0.19 ± 0.18
Week 8
−1.11 ± 0.16 −0.52 ± 0.18
0.008
<0.001
2. Exercise brings on my fatigue.
Week 4
−0.72 ± 0.18 −0.23 ± 0.20
Week 8
−0.59 ± 0.19 −0.09 ± 0.20
0.082
0.028
3. I am easily fatigued.
Week 4
−1.04 ± 0.20 −0.52 ± 0.21
Week 8
−0.94 ± 0.20 −0.67 ± 0.22
0.195
<0.001
4. Fatigue interferes with my physical functioning.
Week 4
−1.30 ± 0.20 −0.43 ± 0.21
Week 8
−1.33 ± 0.20 −0.79 ± 0.22
0.038
<0.001
5. Fatigue causes frequent problems for me.
Week 4
−1.04 ± 0.19 −0.86 ± 0.21
Week 8
−1.31 ± 0.19 −0.89 ± 0.22
0.355
<0.001
6. My fatigue prevents sustained physical functioning.
Week 4
−1.12 ± 0.22 −0.44 ± 0.23
Week 8
−1.10 ± 0.22 −0.43 ± 0.23
0.064
<0.001
7. Fatigue interferes with carrying out certain duties and responsibilities.
Week 4
−0.97 ± 0.18 −0.49 ± 0.20
Week 8
−1.11 ± 0.18 −0.44 ± 0.20
0.071
<0.001
8. Fatigue is among my three most disabling symptoms.
Week 4
−0.93 ± 0.21 −0.55 ± 0.22
Week 8
−1.13 ± 0.21 −0.70 ± 0.22
0.263
<0.001
9. Fatigue interferes with my work, family, or social life.
Week 4
−1.04 ± 0.20 −0.64 ± 0.22
Week 8
−1.18 ± 0.20 −0.66 ± 0.22
0.178
<0.001

0.046

0.023

0.241

0.361

0.030

0.419

0.097

0.058

0.333

0.274

1

LSmean ± SE (all such values). FPP, fermented porcine placenta. 2 Linear mixed-effect model adjusted for dietary
intake and physical activity (MET) was used to analyze group, time and group × time for 8 weeks.

To identify the subjects who showed amelioration of fatigue following FPP supplementation,
we conducted subgroup analyses according to subject age (30–44 years vs. 45–60 years) and BMI
(<23 kg/m2 vs. ≥23 kg/m2 ) (Tables 5 and 6). Cortisol post-AUC area was improved significantly in
subjects younger than 45 years (p = 0.017) following supplementation with FPP compared with placebo
(Table 5). Furthermore, the lactate and myoglobin levels were improved significantly in subjects whose
BMI was ≥ 23 kg/m2 (p = 0.045 and p = 0.011, respectively) upon treatment with FPP versus placebo.
No statistically significant differences were detected in the MDA AUC between the FPP and placebo
groups based on subgroup analysis according to BMI (Table 6).
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Table 5. Effect of fermented porcine placenta supplementation on cortisol according to subgroup 1 .
Age 30–44 Years (n = 39)
FPP
n = 19
Cortisol
AUC (ng/dL × min)
Week 0
26.3 ± 1.5
Week 8
26.0 ± 1.4
Pre-AUC (ng/dL × min)
Week 0
9.4 ± 3.1
Week 8
10.3 ± 2.9
Post-AUC (ng/dL × min)
Week 0
22.3 ± 2.5
Week 8
18.2 ± 2.4

Age 45–60 Years (n = 28)

p-Value 2

p-Value 2

Group × Time

FPP
n = 17

Placebo
n = 11

Group

Time

Group × Time

0.723

0.457

24.1 ± 0.8
23.3 ± 0.7

23.2 ± 0.9
22.8 ± 0.9

0.464

0.473

0.811

0.759

0.317

0.070

8.6 ± 2.1
1.6 ± 2.0

4.4 ± 2.4
4.6 ± 2.5

0.796

0.167

0.126

0.913

0.899

0.017

18.3 ± 1.7
22.8 ± 1.6

21.1 ± 2.0
20.7 ± 2.0

0.863

0.280

0.193

Placebo
n = 20

Group

Time

27.0 ± 1.4
28.0 ± 1.4

0.439

10.9 ± 2.9
6.4 ± 3.0
18.3 ± 2.4
22.8 ± 2.5

1

LSmean ± SE (all such values). FPP, fermented porcine placenta; AUC, area under the curve; FSS, Fatigue severity scale.
physical activity (MET) was used to analyze group, time and group × time for 8 weeks.

2

Linear mixed-effect model adjusted for dietary intake and

Table 6. Effect of fermented porcine placenta supplementation on FSS and biomarker according to subgroup 1 .
BMI < 23kg/m2 (n = 52)
FPP
n = 26
Lactate
AUC (mg/dL × min)
Week 0
1015.7 ± 98.5
Week 8
1211.9 ± 97.9
Pre-AUC (mg/dL × min)
Week 0
375.7 ± 84.2
Week 8
477.3 ± 83.4
Post-AUC (mg/dL × min)
Week 0
659.9 ± 63.9
Week 8
743.9 ± 62.9
Myoglobin AUC (ng/mL × min)
Week 0
2410.7 ± 178.4
Week 8
2796.1 ± 175.2
MDA AUC (pmol/mL × min)
Week 0
12,566.5 ± 1697.1
Week 8
8296.8 ± 1665.1
1

BMI ≥ 23kg/m2 (n = 32)
p-Value 2

p-Value 2

Group × Time

FPP
n = 16

Placebo
n = 16

Group

Time

Group × Time

0.071

0.140

1297.5 ± 136.7
1028.7 ± 133.5

1309.4 ± 182.0
1472.6 ±192.0

0.285

0.604

0.045

0.951

0.079

0.937

647.2 ± 98.1
341.8 ± 95.3

567.2 ± 129.6
588.8 ± 139.1

0.562

0.114

0.074

727.3 ± 54.2
664.1 ± 55.5

0.923

0.858

0.185

662.7 ± 79.9
677.0 ± 77.5

739.8 ± 105.4
884.2 ± 113.4

0.228

0.278

0.337

2480.1 ± 145.1
2380.4 ± 154.9

0.342

0.363

0.108

2653.9 ± 215.2
2281.5 ± 211.1

2639.9 ± 288.6
3018.7 ± 300.5

0.297

0.981

0.011

9184.7 ± 1379.7
7282.1 ± 1472.9

0.198

0.048

0.417

10346.4 ± 1144.5
8734.7 ± 1107.9

9894.4 ± 1504.8
11,354.1 ± 1638.0

0.493

0.948

0.204

Placebo
n = 26

Group

Time

1110.8 ± 84.0
1141.5 ± 85.6

0.917

365.4 ± 71.7
475.5 ± 73.2

LSmean ± SE (all such values). FPP, fermented porcine placenta; AUC, area under the curve; FSS, Fatigue severity scale; MDA, malondialdehyde.
for dietary intake and physical activity (MET) was used to analyze group, time and group × time for 8 weeks.

2

Linear mixed-effect model adjusted
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Over the course of supplements periods, there were 25 supplement-unrelated minor health-related
events (11 in the FPP group, and 14 in the placebo group) confirmed by the physician in charge.
These minor events disappeared after a short period, and the supplements were continued for the
subjects. Furthermore, all the subjects’ safety parameters, such as vitals, hematology, and blood
biochemistry, remained in the physiologically normal range (Table A2).
4. Discussion
To our knowledge, this is the first study to analyze the effects of FPP supplementation on
the time to fatigue recovery in healthy adults after a single session of fatigue-inducing treadmill
test. Based on the physiological properties and beneficial anti-fatigue and performance effects of
FPP [16,19,33–35], we hypothesized that FPP supplementation enhances recovery from exercise-induced
fatigue by improving immune modulation, cellular regeneration, anti-inflammatory cytokine levels,
and physiological responses. Moreover, FSS is a validated questionnaire used to evaluate subjective
fatigue-related symptoms [36,37]. In this study, the changes in FSS total score decreased significantly
in the FPP group compared with the placebo group after 8 weeks of ingestion. The study implied
that the anti-fatigue effects of FPP were controlled by the levels of pro-inflammatory cytokines,
in accordance with previous animal experiments [23]. As hypothesized, we observed that an
8-week FPP supplementation alleviated the fatigue symptoms in the participants without serious
supplement-related side effects.
The double-blind, randomized, placebo-controlled study minimized the chance of bias in sample
selection or interpretation of results. We matched the FPP and placebo groups for age, sex, body composition,
lifestyle, and cardiopulmonary function. Fatigue is a common symptom in various inflammatory
disorders including a variety of illnesses, and was correlated with high levels of inflammatory cytokines
(TNF-α, IL-1, and IL-6), which generate fatigue or other symptoms [38]. It has been suggested that
pro-inflammatory cytokines, especially interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), play a
significant role in fatigue induction. Several studies have been performed to explain the association
between inflammation and these central processes. In particular, IL-1 is of great interest because of its
important role in congenital immune system and other physiological systems. Studies reported the
role of two of the 11 members belonging to the IL-1 family, including IL-1α and IL-1β in fatigue [39–41]
In this study, we have shown that 8-week FPP supplementation improves the level of IL-1β. Therefore,
it is suggested that the anti-fatigue effect of FPP is mediated via regulation of inflammation, and the
anti-fatigue effects result via downregulation of metabolite accumulation in exercise-induced fatigue.
A comprehensive subgroup analysis of the participants according to age (30 to 44 years vs. 45
to 60 years) and BMI (<23 kg/m2 vs. >23 kg/m2 ) levels was conducted. Current studies report that
subjects within the age range of 30 to 40 years generally showed a higher fatigue index than the older
age group [42]. Therefore, our subgroup analysis was consistent with the overall result. Serum cortisol
levels after 8 weeks of treatment were significantly reduced in subgroups of subjects below age 45
(p = 0.017). However, in the opposite subgroup, it did not significantly inhibit fatigue-inducing serum
cortisol levels. Cortisol is a known biomarker of stress induced by physical or psychological stimuli,
and extensive measurements have been conducted to assess physical stress response to strenuous
exercise [43]. In our subjects, serum cortisol levels increased by treadmill exercise were significantly
reduced with FPP treatment, similar to a previous study [23]. These findings indicate that suppressing
exercise-induced physical stress with supplements might effectively alleviate fatigue. Our results
suggest that the anti-fatigue effect of FPP may be mediated via regulation of serum cortisol levels in
human blood.
In the present study, we demonstrated that an 8-week supplementation of FPP was effective
in reducing lactate and myoglobin levels in subgroups with BMI 23 kg/m2 or higher, leading to
protective effects against physical fatigue. These results are similar to the NHANES III study, which
reported that groups with higher fatigue had higher BMI in a cross-section of 3125 adults aged
20 to 59 years, and in this study, the anti-fatigue effect of FPP supplement occurred in groups
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of subjects with BMI greater than 23 kg/m2 [44]. However, the effects of FPP on humans have
yet to be investigated. Our findings are in agreement with a study conducted by Kim et al. [23],
which investigated the effects of FPP powder supplementation on fatigue stress in mice exposed to
exercise-induced physical stress. The findings showed that FPP prevented physical fatigue stress
by decreasing fatigue-related biochemical parameters (lactate and myoglobin) and increasing the
expression of anti-fatigue molecules (SOD, CAT, and glycogen). Lactate is synthesized from pyruvate,
mostly during glucose catabolism via the glycolytic pathway or the breakdown of certain amino acids.
Under normal aerobic conditions, pyruvate is transported into mitochondria, where it is converted to
acetyl-CoA by the pyruvate dehydrogenase (PDH) complex. However, a reduction in PDH enzymatic
activity may lead to accumulation of pyruvate and thereby result in excessive lactate synthesis, despite
adequate oxygen levels [45].
The improved anti-fatigue effects of FPP supplementation may be explained by the levels of bioactive
peptides, such as Gly-Leu and Leu-Gly as demonstrated in the present study [24]. We hypothesize that
FPP supplementation increased fatigue-related anti-inflammatory activity mediated by IL-1β, lactate
and myoglobin activation; however, additional evidence based on clinical trial studies is needed to
corroborate this hypothesis. The changes in FSS total score indicated that FPP alleviated fatigue in
subjects regardless of age or other characteristics. In addition, according to the subgroup analysis,
the group with higher fatigue level tended to be positively affected by the consumption of FPP.
However, the limitation lies with interpreting the FSS and CIS questionnaires in this study.
Although FSS and CIS questionnaires are known and used as reliable tools to assess subjective fatigue
for individuals [37,38], recent studies have reported that individual’s subjective feeling of fatigue
may be influenced by multiple factors. For instance, a study by Loy et al. [46] and Boolani et al. [47]
reported that feeling of fatigue is associated with psychological status, sleep quality as well as a level of
mental working [47,48]. However, the current study was conducted without considering those factors
(e.g., psychological status, sleep quality, and level of mental working). Only limited interpretation
of the FSS and CIS questionnaire results in this study could be made regarding the effect of FPP on
fatigue. Although this study assessed the biomarkers for fatigue in serum (e.g., IL-1β mRNA and
cortisol) to provide the objective measures for fatigue, further researches considering psychological
factor are necessary to understand the effect of FPP on fatigue fully. Furthermore, because CIS also
measures participants’ subjective feelings in strength, muscle function test (e.g., 1RM strength test,
physical function test) may be necessary to provide further in-depth insight into FPP’s role in muscle
function or strength.
5. Conclusions
This study is the first clinical trial demonstrating the role of FPP as an anti-fatigue supplement
and demonstrated that ingestion of 320 mg/day FPP (containing 200 µg of Gly-Leu and Leu-Gly)
significantly ameliorated fatigue-related biochemical parameters and improved fatigue measurement
scales in healthy adults. Our results indicate that FPP supplementation induced the anti-fatigue effect
via the regulation of inflammatory responses and showed the potential uses of FPP for improving
daily life fatigue. However, this study did not examine the potential additive effect of FPP on regular
exercise (resistance exercise or aerobic exercise). Investigating the potential additive effect of FPP to
improve exercise performance or recovery may be the future direction in a study for FPP.
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Appendix A
Table A1. Checklist Individual Strength between groups 1 .
Variables

Placebo

Total
Week 0
76.63 ± 2.78
Week 4
70.19 ± 2.79
Week 8
68.67 ± 2.81
Fatigue severity items
Week 0
32.91 ± 1.45
Week 4
29.38 ± 1.45
Week 8
29.50 ± 1.46
Concentration items
Week 0
18.75 ± 0.83
Week 4
17.47 ± 0.83
Week 8
16.57 ± 0.84
Motivation items
Week 0
13.97 ± 0.68
Week 4
12.99 ± 0.68
Week 8
13.01 ± 0.68
Activity items
Week 0
11.01 ± 0.56
Week 4
10.34 ± 0.56
Week 8
9.60 ± 0.57

FPP

p-Value 2
Group

Time

Group × Time

79.59 ± 2.64
66.85 ± 2.59
65.69 ± 2.60

0.725

<0.001

0.161

35.28 ± 1.37
27.71 ± 1.35
28.44 ± 1.35

0.942

<0.001

0.073

18.79 ± 0.78
16.17 ± 0.77
15.40 ± 0.77

0.383

<0.001

0.434

13.70 ± 0.64
12.26 ± 0.63
11.93 ± 0.63

0.368

0.008

0.664

11.82 ± 0.53
10.71 ± 0.52
9.92 ± 0.53

0.426

<0.001

0.775

1. I feel tired
Week 0
4.58 ± 0.25
4.94 ± 0.24
Week 4
3.95 ± 0.25
3.69 ± 0.24
Week 8
3.86 ± 0.26
4.03 ± 0.24
0.749
<0.001
2. I feel very active
Week 0
3.64 ± 0.27
3.57 ± 0.26
Week 4
3.49 ± 0.27
3.55 ± 0.25
Week 8
3.60 ± 0.27
3.49 ± 0.25
0.901
0.917
3. Thinking requires effort
Week 0
3.68 ± 0.23
3.51 ± 0.22
Week 4
3.30 ± 0.24
2.69 ± 0.22
Week 8
3.10 ± 0.24
2.62 ± 0.22
0.112
<0.001
4. Physically, I feel exhausted
Week 0
3.79 ± 0.27
4.39 ± 0.25
Week 4
3.48 ± 0.27
2.89 ± 0.25
Week 8
3.30 ± 0.27
3.06 ± 0.25
0.762
<0.001
5. I feel like doing all kinds of nice things
Week 0
3.14 ± 0.25
3.29 ± 0.23
Week 4
2.97 ± 0.25
2.92 ± 0.23
Week 8
3.06 ± 0.25
2.92 ± 0.23
0.954
0.348
6. I feel fit
Week 0
3.78 ± 0.23
3.67 ± 0.21
Week 4
3.24 ± 0.23
3.39 ± 0.21
Week 8
3.66 ± 0.23
3.53 ± 0.21
0.896
0.071
7. I think I do a lot in a day
Week 0
3.69 ± 0.22
3.80 ± 0.21
Week 4
3.53 ± 0.22
3.57 ± 0.20
Week 8
3.28 ± 0.22
3.39 ± 0.21
0.708
0.064
8. When I am doing something, I can keep my thoughts on it
Week 0
3.66 ± 0.21
3.60 ± 0.20
Week 4
3.77 ± 0.21
3.34 ± 0.20
Week 8
3.44 ± 0.21
3.14 ± 0.20
0.240
0.102

0.206

0.910

0.390

0.021

0.757

0.662

0.969

0.488
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Table A1. Cont.
Variables

Placebo

FPP

p-Value 2
Group

Time

Group × Time

9. I feel weak
Week 0
4.28 ± 0.24
4.59 ± 0.23
Week 4
3.96 ± 0.24
3.34 ± 0.22
<0.001
Week 8
3.59 ± 0.24
3.71 ± 0.22
0.813
10. I think I do very little in a day
Week 0
3.58 ± 0.24
4.08 ± 0.23
Week 4
3.40 ± 0.25
3.70 ± 0.23
Week 8
3.28 ± 0.25
3.14 ± 0.23
0.399
0.008
11. I find it easy to concentrate
Week 0
3.50 ± 0.21
3.53 ± 0.20
Week 4
3.48 ± 0.21
3.18 ± 0.20
Week 8
3.32 ± 0.21
3.26 ± 0.20
0.630
0.361
12. I feel rested
Week 0
4.33 ± 0.23
4.71 ± 0.22
Week 4
3.55 ± 0.23
3.86 ± 0.22
Week 8
3.86 ± 0.23
3.62 ± 0.22
0.485
<0.001
13. It takes a lot of effort to concentrate on things
Week 0
3.67 ± 0.23
3.72 ± 0.22
Week 4
3.10 ± 0.23
3.27 ± 0.21
Week 8
3.13 ± 0.23
2.96 ± 0.21
0.925
0.002
14. Physically I am in bad shape
Week 0
3.62 ± 0.25
3.90 ± 0.23
Week 4
3.51 ± 0.25
3.29 ± 0.23
Week 8
3.60 ± 0.25
3.07 ± 0.23
0.556
0.055
15. I have a lot of plans
Week 0
3.79 ± 0.23
3.32 ± 0.22
Week 4
3.30 ± 0.23
3.02 ± 0.22
Week 8
3.42 ± 0.23
2.86 ± 0.22
0.093
0.029
16. I tire easily
Week 0
4.43 ± 0.26
5.03 ± 0.24
Week 4
3.80 ± 0.26
3.69 ± 0.24
<0.001
Week 8
3.62 ± 0.26
3.75 ± 0.24
0.480
17. I get little done
Week 0
3.74 ± 0.23
3.96 ± 0.22
Week 4
3.38 ± 0.23
3.42 ± 0.21
Week 8
3.07 ± 0.23
3.41 ± 0.21
0.416
0.003
18. I don’t feel like doing anything
Week 0
3.39 ± 0.25
3.52 ± 0.24
Week 4
3.23 ± 0.25
2.74 ± 0.23
Week 8
2.96 ± 0.25
2.65 ± 0.23
0.377
0.007
19. My thoughts easily wander
Week 0
4.24 ± 0.25
4.44 ± 0.24
Week 4
3.81 ± 0.25
3.67 ± 0.23
Week 8
3.61 ± 0.25
3.41 ± 0.23
0.854
<0.001
20. Physically I feel I am in good shape
Week 0
4.13 ± 0.24
4.08 ± 0.22
Week 4
3.81 ± 0.24
3.46 ± 0.22
Week 8
4.10 ± 0.24
3.71 ± 0.22
0.306
0.028
1

0.019

0.215

0.539

0.235

0.625

0.074

0.689

0.115

0.686

0.286

0.521

0.539

LSmean ± SE (all such values). FPP, fermented porcine placenta. 2 Linear mixed-effect model adjusted for dietary
intake and physical activity (MET) was used to analyze group, time and group × time for 8 weeks.

Nutrients 2020, 12, 3086

13 of 15

Appendix B
Table A2. Hematological test 1 .

White blood cell (103 /µL)
Week 0
Week 8
p-value 3
Red blood cell (106 /µL)
Week 0
Week 8
p-value 3
Hemoglobin (g/dL)
Week 0
Week 8
p-value 3
Hematocrit (%)
Week 0
Week 8
p-value 3
Platelet (103/µL)
Week 0
Week 8
p-value 3
MCV (fL)
Week 0
Week 8
p-value 3
MCH (pg)
Week 0
Week 8
p-value 3
MCHC (g/dL)
Week 0
Week 8
p-value 3

FPP
n = 42

Placebo
n = 42

p-Value 2

5.4 ± 0.2
5.5 ± 0.2
0.937

5.5 ± 0.2
5.4 ± 0.2
0.930

0.929
0.884

4.5 ± 0.1
4.5 ± 0.1
0.289

4.6 ± 0.1
4.7 ± 0.1
0.581

0.547
0.171

13.7 ± 0.2
13.5 ± 0.2
0.180

13.5 ± 0.3
13.5 ± 0.3
1.000

0.714
0.961

41.3 ± 0.6
41.3 ± 0.7
0.984

41.1 ± 0.7
41.5 ± 0.9
0.312

0.829
0.863

269.3 ± 10.1
272.0 ± 10.7
0.805

280.9 ± 10.9
305.2 ± 11.7
0.015

0.499
0.033

91.1 ± 0.6
91.8 ± 0.7
0.064

89.5 ± 1.0
89.2 ± 1.1
0.463

0.161
0.056

30.1 ± 0.3
30.0 ± 0.3
0.411

29.4 ± 0.4
29.1 ± 0.5
0.138

0.191
0.111

33.0 ± 0.2
32.7 ± 0.2
0.022

32.8 ± 0.2
32.6 ± 0.2
0.132

0.463
0.587

1

Mean ± SE (all such values). FPP, fermented porcine placenta. MCV, mean corpuscular volume; MCH,
mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration. 2 Student’s t-test was used to
compare the difference between the groups. 3 Paired t-test was used to compare the difference within each group.
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